Condition

Systemic Sclerosis (SSc) clinical trials and research

• 46Clinical trials
• 2NIH research projects
• 21Countries

Newest Systemic Sclerosis (SSc) clinical trials

All recruiting trials (46)

• Progressive Muscle Relaxation for Fatigue and Breathing in Systemic Sclerosis

  Aims to see if progressive muscle relaxation can help reduce fatigue and breathing difficulties and improve lung function in adults with systemic sclerosis.

  Recruiting University of Gaziantep · Gaziantep, Şehitkamil · NCT07842133

• FT839 therapy for autoimmune diseases

  This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.

  Recruiting Phase 1/2 Fate Therapeutics · Fullerton, California · NCT07800871

• ATG-201 in adults with autoimmune diseases

  This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.

  Recruiting Phase 1 Antengene Corporation · Bengbu, Anhui and 21 other locations · NCT07732309

• Tissue models of systemic sclerosis using patient-derived iPSCs

  Researchers will create iPSC lines from people with systemic sclerosis, their healthy relatives, and test them across several cell types to see how the disease affects tissues in the lab.

  Recruiting University Hospital, Montpellier · Montpellier · NCT07650565

• First-in-human test of PRO-203 in healthy adults and people with systemic sclerosis

  Researchers will test a single subcutaneous dose of PRO-203 in healthy adults and in people with systemic sclerosis to see if it is safe and how the body handles it.

  Recruiting at 12 sites Phase 1/2 Prolium Bioscience, Inc · Melbourne, Victoria and 12 other locations · NCT07641634

• CD19/BCMA UCART for B cell–related autoimmune diseases

  This early-stage study tests QT-219CX, a universal allogeneic CAR-T cell therapy that targets CD19 and BCMA, in people with refractory B-cell–related autoimmune diseases to see if it can be given safely and provide early signs of benefit.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07586267

• MTS109 treatment for refractory autoimmune diseases

  This trial tests whether MTS109 (an mRNA-LNP given by subcutaneous injection) is safe and tolerable in adults with moderate to severe autoimmune diseases that have not responded to standard treatments.

  Recruiting Early Phase 1 Shanghai Changzheng Hospital · Shanghai, Shanghai Municipality · NCT07526350

• Allogeneic CD19/BCMA CAR‑T for B‑cell autoimmune disease

  This Phase 1 study will test a donor-derived CAR‑T therapy that targets CD19 and BCMA to try to reset the immune system in people with refractory B‑cell autoimmune diseases such as SLE, IgA nephropathy, systemic sclerosis, and resistant nephrotic syndrome.

  Recruiting Early Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07507201

• Using long-lived immune cells to calm an overactive immune system

  This trial will try QEL-005, an autologous CD19-directed CAR-T regulatory cell therapy, to calm immune overactivity in adults with diffuse cutaneous systemic sclerosis or difficult-to-treat rheumatoid arthritis.

  Recruiting at 7 sites Phase 1/2 Quell Therapeutics Limited · Düsseldorf and 9 other locations · NCT07473154

• TI-0032-III injection for relapsed and refractory B cell–related autoimmune diseases

  This trial tests whether TI-0032-III, an injected therapy that delivers circular RNA instructions for a CD19 CAR to T cells, can help adults with relapsed or treatment‑resistant B cell–related autoimmune diseases such as SLE, Sjögren's, systemic sclerosis, inflammatory myopathy, or ANCA-associated vasculitis.

  Recruiting Phase 1 Therorna · Shanghai, Shanghai Municipality · NCT07413341

• Long-term follow-up after KYV-101 (CAR T) treatment

  This follow-up will test how long KYV-101 CAR T cells persist and record any delayed side effects in people who previously received KYV-101 for autoimmune diseases like lupus nephritis, myasthenia gravis, stiff person syndrome, rheumatoid arthritis, or multiple sclerosis.

  Recruiting Kyverna Therapeutics · Denver, Colorado · NCT07403188

• Diet approaches for gastrointestinal symptoms in systemic sclerosis

  This project will test whether three different diets reduce bloating and other gastrointestinal symptoms in people with systemic sclerosis.

  Recruiting University of Michigan · Ann Arbor, Michigan · NCT07402226

• Autologous fat‑derived regenerative cell injections for hand problems in systemic sclerosis

  This treatment will try injecting a patient's own fat-derived regenerative cells into the fingers to see if it improves hand function in adults with systemic sclerosis.

  Recruiting at 2 sites Cytori Therapeutics · Guangzhou, Guangdong and 1 other locations · NCT07360808

• Allogeneic CAR T cells targeting CD19 and BCMA for B‑cell autoimmune diseases

  This study will try a single infusion of off‑the‑shelf CAR T cells that target CD19 and BCMA to treat people with B‑cell–mediated autoimmune diseases such as lupus, IgA nephropathy, and drug‑resistant nephrotic syndrome.

  Recruiting Phase 1 The Children's Hospital of Zhejiang University School of Medicine · Hangzhou, Zhejiang · NCT07305116

• BCT301 CAR-iT cell therapy for hard-to-treat autoimmune diseases

  This early‑phase study tests whether off-the-shelf BCT301 CAR-iT cells can be given safely to adults with refractory autoimmune diseases to see if they can be tolerated and what dose works best.

  Recruiting Early Phase 1 Peking University Third Hospital · Beijing · NCT07301164

• Biopsychosocial (BETY) exercise program for children and adults with scleroderma

  This project will test whether BETY, a biopsychosocial exercise program, helps children and adults with scleroderma improve physical function and psychosocial well-being.

  Recruiting Hacettepe University · Ankara, Altındağ · NCT07292961

• Interferon patterns in cancer patients receiving CTLA-4 or PD-1/PD-L1 inhibitors versus autoimmune disease

  This project will test whether blood interferon levels can help predict immune-related side effects in adults starting checkpoint inhibitor immunotherapy by comparing them with people who have autoimmune diseases.

  Recruiting Hospital Universitario Araba · Pamplona, Navarre · NCT07249060

• Topical CBD and urea lotion for itch relief in scleroderma

  This trial will test whether a 10% urea lotion containing 1% cannabidiol (CBD) reduces itching in adults with systemic sclerosis.

  Recruiting Phase 3 Khon Kaen University · Khon Kaen · NCT07245238

• AI-based screening models for pulmonary arterial hypertension in people with systemic sclerosis

  This project will test whether artificial intelligence models using clinical, lab, ECG, and echocardiogram data can better screen adults with systemic sclerosis for pulmonary arterial hypertension.

  Recruiting at 5 sites Hospital Universitario 12 de Octubre · Granada, Andalusia and 4 other locations · NCT07236970

• Measuring calcinosis cutis burden on CT scans

  This project will test software that measures calcinosis cutis on CT images for adults with systemic sclerosis who are receiving sodium thiosulfate as part of their care.

  Recruiting Yale University · New Haven, Connecticut · NCT07228429

• BCMA/CD70-directed CAR-T for children with hard-to-treat rheumatic diseases

  This trial will try a BCMA/CD70-directed CAR-T therapy in children aged 5 and older whose rheumatic diseases have not responded to standard treatments.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Hangzhou, Zhejiang · NCT07184450

• Physical performance and daily function in people with scleroderma

  This project will test which questionnaires and simple physical tests best measure physical performance and daily functioning in children and adults with scleroderma.

  Recruiting Hacettepe University · Çankaya, Ankara · NCT07183072

• Chewing and swallowing performance in people with scleroderma

  This project will see how children and adults with scleroderma chew and swallow and collect biopsychosocial information using questionnaires.

  Recruiting Hacettepe University · Çankaya, Ankara · NCT07182981

• Turkish PASTUL questionnaire for measuring upper‑limb skin thickness in systemic sclerosis

  This project will test a Turkish version of the PASTUL questionnaire to see if people with systemic sclerosis can use it to measure their upper‑limb skin thickness.

  Recruiting Hacettepe University · Çankaya, Ankara · NCT07182968

• OL-CD19-GDT CAR‑T for relapsed or refractory systemic sclerosis and primary Sjögren's syndrome

  This trial will try the CAR‑T therapy OL‑CD19‑GDT in adults whose systemic sclerosis or primary Sjögren's syndrome has relapsed or not responded to other treatments to see if it is safe and helps.

  Recruiting Phase 1 Beijing GoBroad Hospital · Beijing · NCT07167537

• Personalized lab test to predict the best treatment for rheumatic diseases

  This project tests a lab-based cell assay to see if it can predict which DMARD will work best for adults with autoimmune rheumatic diseases such as RA, PsA, axSpA, and GCA.

  Recruiting University of Bonn · Bonn, North Rhine-Westphalia · NCT07150000

• YTS109 cell therapy for relapsed or refractory autoimmune diseases

  This trial will try a single infusion of YTS109 cells to see if they are safe and help adults (18–65) with relapsing or refractory autoimmune diseases such as SLE, lupus nephritis, systemic sclerosis, inflammatory myopathy, or ANCA-associated vasculitis.

  Recruiting Phase 1 China Immunotech (Beijing) Biotechnology Co., Ltd. · Hefei, Anhui · NCT07104721

• Butantan live tetravalent dengue vaccine for people with autoimmune rheumatic diseases

  This study will test whether a single dose of the Butantan live tetravalent dengue vaccine is safe and produces immune responses in clinically stable people aged 12–59 with autoimmune rheumatic diseases compared with matched healthy volunteers.

  Recruiting at 2 sites Phase 4 University of Sao Paulo General Hospital · São Paulo, São Paulo and 1 other locations · NCT07087912

• HBI0101 CAR-T for refractory B‑cell autoimmune rheumatic diseases

  This will test a single infusion of HBI0101 CAR‑T cells in adults with severe, treatment‑resistant B‑cell autoimmune diseases such as SLE, systemic sclerosis, idiopathic inflammatory myopathy, rheumatoid arthritis, or primary progressive MS.

  Recruiting Phase 1 Hadassah Medical Organization · Jerusalem · NCT07085676

• UTAA91 injection for refractory systemic sclerosis

  This trial will test whether UTAA91 injections are safe and tolerable in adults with refractory moderate-to-severe systemic sclerosis.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07000682

• AlloNK® therapy combined with rituximab for treating certain autoimmune diseases

  This study is testing if a new treatment called AlloNK® combined with rituximab can help people with tough-to-treat autoimmune diseases feel better.

  Recruiting at 52 sites Phase 2 Artiva Biotherapeutics, Inc. · Tuscaloosa, Alabama and 51 other locations · NCT06991114

• Evaluating OL-108 for autoimmune diseases that have not responded to previous treatments

  This study is testing a new treatment called OL-108 to see if it can help people with autoimmune diseases that haven't improved with other therapies.

  Recruiting at 2 sites Phase 1 Beijing GoBroad Hospital · Beijing and 1 other locations · NCT06980597

• YTS109 cell therapy for relapsed or refractory systemic autoimmune diseases

  This trial will try a single infusion of YTS109 cells to see if it's safe and helps adults 18–65 with relapsed or refractory systemic autoimmune diseases such as SLE, systemic sclerosis, inflammatory myopathies, ANCA-associated vasculitis, or antiphospholipid syndrome.

  Recruiting Phase 1 China Immunotech (Beijing) Biotechnology Co., Ltd. · Beijing, Beijing Municipality · NCT06978647

• CAR T-cell therapy for autoimmune diseases

  This study is testing a new CAR T-cell therapy to see if it can help people with tough autoimmune diseases like lupus and systemic sclerosis feel better.

  Recruiting Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT06941129

• Understanding skin health in systemic sclerosis

  This study looks at how systemic sclerosis affects skin health by comparing skin samples and blood from people with the condition to those without it.

  Recruiting Relation Therapeutics · Leeds and 1 other locations · NCT06894654

• Safety evaluation of CC312 in patients with autoimmune diseases

  This study is testing a new treatment called CC312 to see if it's safe and tolerable for adults with autoimmune diseases like lupus and rheumatoid arthritis.

  Recruiting Early Phase 1 CytoCares Inc · Tianjin, China · NCT06888960

• Home monitoring for cardiac issues in systemic sclerosis patients

  This study is testing if home monitoring can help people with systemic sclerosis-related lung high blood pressure keep track of their symptoms and health better than regular hospital visits.

  Recruiting Oslo University Hospital · Oslo · NCT06865118

• Universal CD19-targeting CAR-γδT cell therapy for refractory autoimmune diseases

  This trial will try infusing universal CD19-targeting CAR-γδT cells into adults with refractory B cell–driven autoimmune diseases to see if removing autoreactive B cells improves symptoms.

  Recruiting Phase 1/2 Peking University Third Hospital · Beijing · NCT06828042

• CT1190B treatment for severe lupus and scleroderma

  This study is testing a new CAR-T cell therapy called CT1190B to see if it can help adults with severe lupus or scleroderma who haven't responded to other treatments.

  Recruiting Phase 1 Beijing GoBroad Hospital · Beijing, Beijing Municipality · NCT06822881

• BCMA-CD19 CAR-T therapy for autoimmune diseases

  This study is testing a new CAR-T cell therapy to see if it can help adults with tough autoimmune diseases feel better and improve their health.

  Recruiting Phase 2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT06794008

• Zamtocabtagene Autologous CAR-T for Autoimmune Diseases

  This early-phase study tests whether a patient’s own CAR-T cells (zamto-cel) can be safely given after standard therapy to people with lupus or systemic sclerosis.

  Recruiting Phase 1 Miltenyi Biomedicine GmbH · Milwaukee, Wisconsin · NCT06708845

• Using a wearable device to improve symptoms in systemic sclerosis patients

  This study is testing if wearing a special device can help people with systemic sclerosis feel less tired and manage their symptoms better.

  Recruiting at 4 sites University of Pittsburgh · New Orleans, Louisiana and 3 other locations · NCT06675344

• Injection of sodium thiosulfate for treating calcinosis

  This study is testing if injections of sodium thiosulfate can safely help people with calcinosis related to conditions like systemic sclerosis and dermatomyositis feel better and reduce their symptoms.

  Recruiting Phase 2 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT06672822

• Using engineered immune cells to treat difficult autoimmune diseases

  This study is testing if a new type of immune cell treatment can help people with tough autoimmune diseases that haven't responded to other therapies.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06614270

• Evaluating FT819 for autoimmune diseases

  This study is testing a new treatment called FT819 to see if it can safely help people with moderate to severe autoimmune diseases feel better.

  Recruiting at 21 sites Phase 1 Fate Therapeutics · Beverly Hills, California and 20 other locations · NCT06308978

• C-CAR168 treatment for autoimmune diseases not responding to standard therapy

  This study is testing a new treatment called C-CAR168 to see if it can help adults with autoimmune diseases that haven't improved with standard therapies.

  Recruiting Phase 1 RenJi Hospital · Shanghai, Shanghai Municipality · NCT06249438

NIH-funded research (2)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Understanding how RUNX1 contributes to skin fibrosis in systemic sclerosis.

  This study is looking at how a protein called RUNX1 affects skin thickening in people with systemic sclerosis, a condition that causes hardening of the skin, to help find new ways to treat it and improve patients' lives.

  NIH research Dartmouth College · Hanover, United States · NIH-11070677

• Understanding and improving treatment for systemic sclerosis vasculopathy

  This study is looking at how systemic sclerosis affects blood vessels, especially in the digestive system, to find better ways to monitor and treat patients like you.

  NIH research Veterans Health Administration · Nashville, United States · NIH-11044090

Related topics

Quick answers

How many Systemic Sclerosis (SSc) clinical trials are recruiting right now?

46, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 21 countries. The most sites are in China (22 trials), United States (9 trials), Turkey (Türkiye) (5 trials), Spain (4 trials), France (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 14, Early Phase 1: 6, Phase 1/2: 4, Phase 2: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →